摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N,N-二甲基 5-溴吡啶-3-磺酰胺 | 896160-99-9

中文名称
N,N-二甲基 5-溴吡啶-3-磺酰胺
中文别名
N,N-二甲基5-溴吡啶-3-磺酰胺
英文名称
5-bromo-N,N-dimethylpyridine-3-sulfonamide
英文别名
5-bromopyridine-3-sulfonic acid dimethylamide;5-bromo-pyridine-3-sulfonic acid diethylamide;5-bromo-N,N-dimethyl-3-pyridinesulfonamide
N,N-二甲基 5-溴吡啶-3-磺酰胺化学式
CAS
896160-99-9
化学式
C7H9BrN2O2S
mdl
——
分子量
265.131
InChiKey
UHJBBAOJADKLCO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    352.8±52.0 °C(Predicted)
  • 密度:
    1.612±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    58.6
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2935009090

SDS

SDS:170cd806c93b54e0f890e19d4db01f3f
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: N,N-Dimethyl 5-bromopyridine-3-sulfonamide
Synonyms: 5-Bromo-N,N-dimethylpyridine-3-sulfonamide

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: N,N-Dimethyl 5-bromopyridine-3-sulfonamide
CAS number: 896160-99-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H9BrN2O2S
Molecular weight: 265.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N,N-二甲基 5-溴吡啶-3-磺酰胺1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 potassium acetatepotassium carbonate 作用下, 以 1,4-二氧六环 为溶剂, 反应 18.0h, 生成 5-(2-amino-4-oxo-3-phenyl-3,4-dihydro-6-quinazolinyl)-N,N-dimethyl-3-pyridinesulfonamide
    参考文献:
    名称:
    [EN] QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS
    [FR] DÉRIVÉS DE QUINAZOLINONE EN TANT QU'AGENTS ANTIVIRAUX
    摘要:
    提供了化合物及其药用盐,它们的药物组合物,它们的制备方法,以及它们用于治疗由黄病毒科(Flaviviridae)家族成员介导的病毒感染,如丙型肝炎病毒(HCV)的用途。
    公开号:
    WO2012087938A1
  • 作为产物:
    描述:
    5-溴吡啶-3-磺酰氯二甲胺三乙胺 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 1.0h, 以60%的产率得到N,N-二甲基 5-溴吡啶-3-磺酰胺
    参考文献:
    名称:
    AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS
    摘要:
    本发明提供了式I的氮杂杂环衍生物及其药学上可接受的盐,其中X、Y、Z、A、W、R4、R5和R6在此处定义,并且抑制磷脂酰肌醇3-激酶γ(PI3Kγ)的活性,并且在治疗与PI3Kγ活性相关的疾病方面具有用处,例如自身免疫疾病、癌症、心血管疾病和神经退行性疾病。
    公开号:
    US20160229843A1
点击查看最新优质反应信息

文献信息

  • [EN] PHENOXY ACETIC ACID DERIVATIVES<br/>[FR] DÉRIVÉS D'ACIDE PHÉNOXYACÉTIQUE
    申请人:MERCK SERONO SA
    公开号:WO2010092043A1
    公开(公告)日:2010-08-19
    The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.
    本发明提供了用于治疗与CRTH2相关的疾病和疾病(包括哮喘、特应性皮炎和炎症性皮肤病)的Formula(I)的苯氧乙酸衍生物。
  • [EN] 5-PYRIDIN-3-YL-1,3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1<br/>[FR] DÉRIVÉS DE 5-PYRIDIN-3-YL-1,3-DIHYDRO-INDOL-2-ON ET LEUR UTILISATION EN TANT QUE MODULATEURS DE L'ALDOSTÉRONE SYNTHASE ET/OU DE LA CYP11B1
    申请人:NOVARTIS AG
    公开号:WO2010130794A1
    公开(公告)日:2010-11-18
    The present invention provides a compound a formula (I); or a pharmaceutically acceptable salt thereof, wherein: X is CH2, O, S or-NR1; each R1 are independently C1-7alkyl or C3-8cycloalkyl; each of R2 and R6 are independently hydrogen, halogen, cyano, C1-7alkyl, hydroxy-C1-7alkyl, -OR7, C3-8cycloalkyl, halo-C1-7alkyl or -CH2-NR8-SO2-R10; R3 and R4 are independently hydrogen, halogen or cyano; R5 is hydrogen, C1-2alkyl, halogen, cyano, hydroxy, hydroxy-C1-7alkyl, hydroxy-C3-8 cycloalkylalkyl, C1-7alkoxy-C3-3alkyl, -OR7, C6-10aryl, heteroaryl, heterocyclyl, C3-8 cycloalkyl, halo- C1-7alkyl, -NR8R9, -CH2NR8-C(O)NR8R9, -CH2-NR6-SO2-R10, -C(O)- R10, -SO2R10, -C(O)-NR5R9 -SO2-NR8R9, -NR3C(O)-R10 -CH2CN, or -NR8-SO2-R10. Compounds of the invention may be useful in the treatment of a disorder or disease mediated by aldosterone synthase and/or 11-beta hydroxylase (CYP1 181).
    本发明提供了一种化合物的结构式(I);或其药用可接受的盐,其中:X为CH2、O、S或-NR1;每个R1独立地为C1-7烷基或C3-8环烷基;每个R2和R6独立地为氢、卤素、氰基、C1-7烷基、羟基-C1-7烷基、-OR7、C3-8环烷基、卤基-C1-7烷基或-CH2-NR8-SO2-R10;R3和R4独立地为氢、卤素或氰基;R5为氢、C1-2烷基、卤素、氰基、羟基、羟基-C1-7环烷基、羟基-C3-8环烷基、C1-7烷氧基-C3-3烷基、-OR7、C6-10芳基、杂环芳基、杂环基、C3-8环烷基、卤基-C1-7烷基、-NR8R9、-CH2NR8-C(O)NR8R9、-CH2-NR6-SO2-R10、-C(O)-R10、-SO2R10、-C(O)-NR5R9-SO2-NR8R9、-NR3C(O)-R10-CH2CN或-NR8-SO2-R10。本发明的化合物可能在治疗由醛固酮合酶和/或11-β羟化酶(CYP1 181)介导的疾病或紊乱中有用。
  • [EN] INDOLIN-2-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CNS DISEASES<br/>[FR] DÉRIVÉS D'INDOLINE-2-ONE UTILES DANS LE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL
    申请人:HOFFMANN LA ROCHE
    公开号:WO2017076932A1
    公开(公告)日:2017-05-11
    The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein A is phenyl or a six membered heteroaryl group, containing one or two N atoms, selected from (II) R1 is S(0)2lower alkyl, S(0)2NR4R5, S(0)2cycloalkyl, S-lower alkyl or S(0)2-azetidin-l-yl; R4 and R5 are independently from each other hydrogen, lower alkyl or (CH2)2OCH3; or the group A-R1 may form together with two neighboring carbon atoms from the group A an additional fused ring, selected from (III) R 2 is hydrogen or cycloalkyl; R 3 is methyl or halogen; n is 1 or 2; X is N, N+0" or CH; --- the dotted line may be nothing or -CH2-; as well as with a pharmaceutically acceptable salt thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive- compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co- morbid epilepsy.
    本发明涉及一种通式(I)的吲哚啉-2-酮衍生物,其中A为苯基或含有一个或两个N原子的六元杂环烃基,选自(II)中;R1为S(0)2较低烷基,S(0)2NR4R5,S(0)2环烷基,S-较低烷基或S(0)2-氮杂环丙烯基;R4和R5分别独立地为氢、较低烷基或(CH2)2OCH3;或者基团A-R1可以与基团A中的两个相邻碳原子一起形成一个来自(III)中选择的额外融合环;R2为氢或环烷基;R3为甲基或卤素;n为1或2;X为N、N+0"或CH;---虚线可以为无或-CH2-;以及其药学上可接受的盐、外消旋混合物或其相应的对映体和/或光学异构体和/或立体异构体。这些化合物可用于治疗与精神病(精神病)、精神分裂症的阳性和阴性症状、物质滥用、酒精和药物成瘾、强迫-强迫性障碍、认知障碍、双相障碍、情绪障碍、重度抑郁症、治疗难治性抑郁症、焦虑障碍、阿尔茨海默病、自闭症、帕金森病、慢性疼痛、边缘人格障碍、神经退行性疾病、睡眠障碍、慢性疲劳综合征、僵硬、炎症性疾病、哮喘、亨廷顿病、注意力缺陷多动障碍、肌萎缩侧索硬化、关节炎效应、自身免疫疾病、病毒和真菌感染、心血管疾病、眼科学和炎症性视网膜疾病和平衡问题、癫痫和伴发癫痫的神经发育障碍相关的中枢神经系统疾病的治疗。
  • Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives
    申请人:Novartis AG
    公开号:US20130165436A1
    公开(公告)日:2013-06-27
    The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R 1 , R 5 , R 7 and R 30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    该发明涉及式(I)的二氢苯并噁嗪和二氢吡啶噁嗪化合物,以及其药学上可接受的盐和/或溶剂化合物,其中Y、V、W、U、Q、R1、R5、R7和R30如描述中所定义。这些化合物适用于治疗由PI3K酶活性介导的疾病或疾病。
  • PHENOXY ACETIC ACID DERIVATIVES
    申请人:Crosignani Stefano
    公开号:US20110288066A1
    公开(公告)日:2011-11-24
    The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.
    本发明提供了公式(I)的苯氧乙酸衍生物,用于治疗与CRTH2相关的疾病和疾病,包括哮喘,特应性皮炎和炎症性皮肤病。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-